---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-269442"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:51:42.369273+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# IN8bio Q3 net loss $3.9M ($0.85/share); cash $10.7M; INB-619/100 updates

## Summary
- Net loss of $3.9M in Q3 2025 vs $7.1M in Q3 2024; basic and diluted EPS -$0.85 vs -$4.49.
- R&D expenses $2.1M (down from $3.3M); G&A $1.9M (down from $2.7M) due to cost-saving measures.
- Cash $10.7M as of Sep 30, 2025, up from $4.0M year-over-year.
- INB-619 preclinical data at ACR showed B cell elimination similar to blinatumomab/mosunetuzumab with minimal cytokine release.
- INB-100 Phase 1 trial expanded to The Ohio State University to accelerate enrollment; updated GBM data planned at SNO Nov 2025.

## SEC filing metadata
- accession: 0001193125-25-269442
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000119312525269442/0001193125-25-269442-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000119312525269442/inab-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-269442
- JSON: https://secwatch.observer/filing/0001193125-25-269442.json
- Plain text: https://secwatch.observer/filing/0001193125-25-269442.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.